NOVARTIS - The Swiss drugmaker has a blockbuster cancer drug and billions in the bank. Now, Daniel Vasella is overhauling how Novartis develops new treatments and laying the groundwork for acquisitions, including, possibly, crosstown rival Roche Group. It's all part of his grand plan to catapult this once-sleepy conglomerate, currently No. 6 in the world, into the pantheon of global pharma giants